Benzinga | May 3, 2021 09:07AM EDT

Natera To Present New Colorectal Cancer And Multiple Myeloma Data At The 2021 Annual ASCO Meeting Jun. 4-8

Natera, Inc. (NASDAQ:NTRA), a pioneer and global leader in cell-free DNA testing, today announced it will present 4 posters at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 4-8, 2021. These presentations will highlight the unique applications of the Signatera molecular residual disease (MRD) test in colorectal cancer and multiple myeloma.

This comes on top of two new studies that were recently presented at the American Association for Cancer Research (AACR) annual meeting. One study reported superior performance by Signatera compared to standard of care CA-125, in detection of cancer recurrence with 100% sensitivity and specificity on average 10 months ahead of radiological findings, among 25 patients with early-stage ovarian cancer who were tested serially after surgical resection.1 The other study at AACR reported a stronger clinical benefit when using Natera's method for quantifying ctDNA levels using an absolute measure of mean tumor molecules per milliliter of plasma (MTM/mL); instead of the more common variant allele frequency (VAF) used by other ctDNA tests, which can be confounded by significant changes in the background cell-free DNA caused by biological factors unrelated to the cancer.2

"We look forward to presenting these groundbreaking new results at this year's ASCO conference, in particular the CIRCULATE-Japan data that should set a new benchmark for MRD assay performance in the context of the largest prospective multicenter study of its kind," said Alexey Aleshin, M.D., M.B.A., vice president of medical affairs, oncology, at Natera. "We are also excited to be sharing new evidence on the clinical validity of Signatera in a number of new cancer types, further demonstrating our commitment to advancing the field of MRD testing across solid tumors."

The ASCO abstract titles are as follows:

Abstract # 3540 | Serial circulating tumor DNA analysis for assessment of recurrence risk, benefit of adjuvant therapy, growth rate and early relapse detection in patients with stage III colorectal cancer

Abstract # 8029 | Personalized, ctDNA analysis to detect minimal residual disease and identify patients at high risk of relapse with multiple myeloma

Abstract # 3608 | Minimal Residual Disease by Circulating Tumor DNA Analysis for Colorectal Cancer Patients Receiving Radical Surgery: An Initial Report form CIRCULATE-Japan

Abstract # 4103 | Tumor-informed assessment of circulating tumor DNA and its incorporation into practice for patients with hepatobiliary cancers